IntroductIon The clinical course of essential thrombocythemia (ET) is varied, and some patients do not exhibit any clinical signs of the disease at the time of diagnosis. The most frequent complications that occur during the course of ET are hemostasis abnormalities manifesting as hemorrhagic or thrombotic events. The mechanism of thrombotic events in patients with ET is complex and not fully understood.
vein, mesenteric, lower extremity, pulmonary embolism), or in the microcirculation (headache, paresthesia, erythromelalgia). 1,2 There are 2 major risk factors of thrombotic events: age above 60 years and a history of thrombotic episodes. Recent studies have indicated that platelet function abnormalities, leukocytosis, activation of platelet -leukocyte aggregates, and the JAK2 V617F mutation may play an important role in the development of thrombotic complications in patients with ET.
3,4
IntroductIon Essential thrombocythemia (ET) belongs to Ph-negative myeloproliferative neoplasms and is characterized by an increased platelet count (>450 G/l) induced by clonal proliferation of megakaryocytes in the bone marrow. ET is mostly diagnosed between 50 and 60 years of age. The JAK2 V617F mutation is found in approximately 50% of patients with ET.
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Thrombotic complications are one of the most common causes of death in patients with ET and can occur in arterial vessels (cerebrovascular or cardiovascular events), venous vessels (splanchnic disease were defined as major arterial thrombotic complications. Major venous thrombotic complications were defined as deep vein thrombosis and mesenteric venous thrombosis.
The control group consisted of 30 healthy volunteers (13 women, 17 men; mean age, 49 years). The study was approved by the Bioethics Committee of Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń (no. KB/396/2010). All patients were informed of the investigational nature of this study and gave written informed consent to participate.
blood collection and measurement of tissue factor and tissue factor pathway inhibitor activity Blood samples were taken from an anticubital vein, after an overnight fasting, to plastic tubes containing 3.2% sodium citrate (anticoagulant:blood, 1:9). Samples were centrifuged at 3000 × g for 20 minutes at 4°C. The obtained plasma was divided into aliquots and stored at -80°C until analysis, but no longer than 6 months. In plasma, the following tests were performed using an enzyme-linked immunosorbent assay (ELISA): concentration of TF (Imubind Tissue Factor ELISA kit, American Diagnostica Inc., Stamford, Connecticut, United States), TF activity (ACTICHROME®TF, American Diagnostica Inc.), concentration of TFPI (Imubind Total TFPI ELISA kit, American Diagnostica Inc.) and TFPI activity (ACTICHROME®TFPI Activity Assay, American Diagnostica Inc.).
JAK2 V617F mutation analysis The JAK2 V617F mutation was detected using allele-specific polymerase chain reaction (allele specific PCR amplification [AS-PCR]). Genomic DNA was isolated from peripheral EDTA blood (QIAamp DNA Mini Kit, Qiagen, Hilden, Germany) from patients with ET. The PCR reaction was performed using 100 ng of DNA, according to the method of Baxter et al.
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During the AS-PCR, the reaction products were 203 bp and 364 bp in length. The 203-bp products indicated the V617F mutation, while the 364 bp products indicated the internal control.
statistical analysis A statistical analysis was performed with the use of Statistica 10 software (StatStoft®, Kraków, Poland). The Shapiro-Wilk According to the cellular theory of blood coagulation, tissue factor (TF)-dependent extrinsic pathway is essential for the activation of blood clotting. TF is released from damaged endothelial cells and activated monocytes, macrophages, leukocytes, and platelets. Microparticles derived from endothelial cells, vascular smooth muscle cells, leukocytes, and platelets may also be the source of TF. 5, 6 The activity of TF is regulated by tissue factor pathway inhibitor (TFPI). TFPI is a Kunitz-type protein that is released from endothelial cells, platelets, monocytes, fibroblasts, and mesangial cells. TFPI inactivates the TF/VIIa complex in 2 steps. In the first phase, TFPI binds to activated factor X (Xa) and forms the TFPI/Xa complex. In the second step, the TFPI/Xa complex inactivates the TF/VIIa complex. TFPI may also directly inhibit the complex of TF/VIIa/Xa in the presence of calcium ions. 7 The aim of the study was to evaluate the procoagulant potential reflected by TF and TFPI activity in patients with ET, with respect to the following risk factors of thrombosis: age above 60 years, history of thrombosis, presence of the JAK2 V617F mutation, and leukocyte count exceeding 10 × 10 9 /l. Data are presented as median (min-max) unless stated otherwise.
Abbreviations: NS, nonsignificant
A detailed analysis of the studied parameters revealed that in 75 patients with ET with the JAK2 V617F mutation, TFPI activity was significantly lower than in patients without the mutation (FIGure 1). However, there were no significant differences in the concentration of TF and TFPI as well as TF activity in patients with ET who had the JAK2 V617F mutation compared with the values obtained in patients without the mutation.
As shown in FIGure 2, the TF concentration was significantly higher (P <0.05) in patients with ET with a history of thrombotic episodes, compared with patients without such episodes (FIGure 2).
There were no significant differences in the activity of TF in patients with a history of thrombosis compared with patients without such history. The concentration and activity of TFPI in patients with a history of thrombotic episodes did not differ significantly from the values obtained in patients with no history of thrombotic events.
There were no significant differences in the concentration and activity of TF and TFPI between patients aged 60 years or older (71 patients) and those younger than 60 years of age (42 patients). Moreover, the concentration and activity of TF and TFPI in patients with ET were not related to leukocyte count. Data are presented in tAble 4. dIscussIon TF is a glycoprotein with a molecular weight of 47 kDa, produced by the brain, lung, placenta, and heart muscle cells. IT occurs in the blood of healthy subjects only in small amounts. Increased concentrations of TF can result from vascular endothelial damage or blood cell activation (platelets, granulocytes). According to recent studies, TF is a major activator of the blood coagulation process. 9, 10 Our study demonstrated a 2-fold higher concentration of TF in patients with ET than in healthy subjects. We determined the procoagulant activity of TF, which is the best indicator of the activation of the blood coagulation process (TF activity). TF activity was nearly 18-fold higher in patients with ET than in healthy subjects.
test was used to assess the normality of the distribution. All studied parameters had abnormal distribution and were presented as a median and lower and upper quartiles. The Mann-Whitney test was used to compare the difference between the groups. Spearman correlation coefficients were calculated to determine any correlations between the parameters. A P value of less than 0.05 was considered statistically significant.
results tAble 1 shows a comparison of blood cell counts between patients with ET and healthy participants. Patients with ET had a 3-fold higher median platelet count (820 × 10 9 /l vs 250 × 10 9 /l; P <0.05) and significantly higher leukocyte count than controls (9.9 × 10 9 /l vs 5.9 × 10 9 /l; P <0.05). Among 113 patients with ET, 21 (18.6%) reported the incidence of arterial and venous thrombotic history. The presence of the JAK2 V617F mutation was observed in 75 patients (66.4%). Data are shown in tAble 2. As shown in tAble 3, patients with ET had more than 2-fold higher TF concentrations and 18-fold higher TF activity, as compared with controls (P <0.000001 for both comparisons). In addition, patients with ET had a significantly higher activity of TFPI, as compared with controls (P <0.05). There were no significant differences in the concentration of TFPI between the groups. a history of thrombosis, patients' age, leukocyte count, and the presence of the JAK2 V617F mutation. We showed significantly higher TF concentrations in patients with ET with past thrombotic episodes. Different results were obtained by Arellano-Rodrigo et al, 9 who found no significant differences in the concentration of TF between patients with ET with and without a history of thrombotic episodes.
Procoagulant activity of TF is inhibited by TFPI, an inhibitor of the TF pathway whose primary source is the vascular endothelium. In the present study, we observed an increased activity of TFPI in patients with ET, as compared with the control group (P = 0.017). The TFPI concentration and activity in patients with ET were also measured by Cacciola et al, 13 who found significantly higher levels of TFPI in these patients (n = 17). Elevated concentrations of TFPI have also been observed in patients with advanced pancreatic, colorectal, stomach, breast, and prostate cancers.
14 It is believed that the increased level of TFPI can A review of the available literature has shown that there are only a few studies assessing the concentration of TF in patients with ET. Panova-Noeva et al 11 observed a significantly higher expression of TF on platelets in patients with ET compared with controls. The authors observed the generation of thrombin in the calibrated automated thrombogram assay in platelet-rich plasma and isolated platelets, but it was absent in platelet-free plasma. According to the authors, platelets (which are the main source of TF) are responsible for the occurrence of a hypercoagulable state in patients with ET. 11 Falanga et al 12 also observed a significantly increased expression of TF on platelets in patients with ET in comparison with the control group. Different results were obtained by Arellano-Rodrigo et al, 9 who did not observe significant differences in the expression of TF on platelets and its concentrations between patients with ET and healthy subjects.
In the current study, we analyzed the concentration and activity of TF and TFPI depending on leukocyte count at diagnosis is a poor prognostic factor and is associated with worse survival. 22 High leukocytosis is also linked to more frequent progression of ET to acute leukemia or myelofibrosis. Carobbio et al 23 observed that the risk of thrombotic events in patients with ET with an increased leukocyte count (above median) was 2-fold higher than that in patients with lower white blood cell count. Based on these results, the authors found that the number of leukocytes can be a useful parameter in evaluating the risk of thrombotic events in patients with ET. 23 Similar conclusions were drawn by Wolanskyj et al, 24 who also reported a relationship between the elevated levels of leukocytes and the incidence of thrombotic events in patients with ET.
In conclusion, the study showed that increased blood coagulation observed in patients with ET may be related to elevated TF concentrations and remarkably increased TF activity. Moreover, in patients with ET with a history of thrombosis or the JAK2 V617F mutation, an enhanced risk of thrombosis may be a result of increased TF concentration or decreased activity of TFPI.
contribution statement KS and GG were responsible for collecting the material for research, analysis, and interpretation of the results. KS and DR were responsible for interpretation of the results and preparation of the manuscript. JB, MM, and AB-K were responsible for the measurement of the parameters. JB was responsible for statistical analysis and preparation of the manuscript. be the result of endothelial damage or increased procoagulant activity of TF. 15 The analysis of TFPI depending on the JAK2 V617F mutation revealed differences in the activity of TFPI between the subgroups with and without the mutation. We found a significantly reduced TFPI activity in patients with ET with the JAK2 V617F mutation, compared with patients without the mutation. Data from the literature suggest that reduced activity of TFPI is associated with an increased risk of thromboembolic incidents. [16] [17] [18] Taken together, the decreased activity of TFPI in patients with the JAK2 V617F mutation indicates that this subgroup can be particularly vulnerable to the risk of thrombosis. Campbell et al 19 found that the incidence of thrombotic complications in the veins was higher in patients with ET with the JAK2 V617F mutation, as compared with patients without the mutation. However, the authors did not observe significant differences in arterial thrombotic events between patients with and without the JAK2 mutation. 19 Antonioli et al 20 reported no relationship between the presence of the JAK2 V617F mutation and the incidence of thrombotic events.
According to prospective and retrospective studies, one of the main risk factors of thrombosis in patients with ET is age above 60 years.
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In the present study, we did not observe any significant differences in TF and TFPI activity and concentration in the subgroups of patients aged less than 60 years and those aged 60 years or older. Thrombotic potential increases with age in healthy subjects. It is associated with vascular endothelial damage, impaired fibrinolysis, and increased concentrations of most procoagulant factors. Therefore, it is believed that risk factors such as age above 60 years and a history of thromboembolic events are associated with abnormalities in the vessels regardless of myeloproliferative neoplasm.
The analysis showed no significant differences in the activity and concentration of TF and TFPI depending on the leukocyte count in the blood of patients with ET. It is well known that high tAble 4 Concentration and activity of tissue factor and tissue factor pathway inhibitor in patients with essential thrombocythemia depending on age and leukocyte count Parameter Age P value Leukocyte count P value <60 years (n = 42) ≥60 years (n = 71) <10×10 9 /l (n = 65) ≥10×10 9 /l (n = 48) 
NS
Data are presented as median and lower and upper quartiles (Q1; Q3).
Abbreviations: see tAble 1 
